6,641 results match your criteria adenoviral replication

[Infectivity of Human Adenovirus Type 55 to Human Intestinal Cells].

Sichuan Da Xue Xue Bao Yi Xue Ban 2021 Mar;52(2):202-206

Department of Clinical Laboratory, the General Hospital of Western Theater Command, Chengdu 610083, China.

Objective: To examine the infectivity of human adenovirus type 55 (HAdV-55) in human intestinal cells.

Methods: Caco-2 cells were cultured , and infected with HAdV-3, 7, 14 and 55. The expression of viral proteins in infected cells was detected with immunofluorescence method. Read More

View Article and Full-Text PDF

Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.

Viruses 2021 Mar 15;13(3). Epub 2021 Mar 15.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.

Lassa virus (LASV) is a rodent-borne arenavirus circulating in West African regions that causes Lassa fever (LF). LF is normally asymptomatic at the initial infection stage, but can progress to severe disease with multiorgan collapse and hemorrhagic fever. To date, the therapeutic choices are limited, and there is no approved vaccine for avoiding LASV infection. Read More

View Article and Full-Text PDF

SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.

Genome Med 2021 03 15;13(1):43. Epub 2021 Mar 15.

School of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of Bristol, Bristol, BS8 1TD, UK.

Background: ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene.

Methods: We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. Read More

View Article and Full-Text PDF

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.

Vaccine 2020 Oct 3. Epub 2020 Oct 3.

Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.

Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development. A replication-incompetent adenoviral vector based on human adenovirus type 26 (Ad26) has been evaluated in several clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and features of recombinant viral vector vaccines. Read More

View Article and Full-Text PDF
October 2020

Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus.

Int J Mol Sci 2021 Feb 18;22(4). Epub 2021 Feb 18.

Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawinskiego 5, 02-106 Warsaw, Poland.

Adenovirus infections tend to be mild, but they may pose a serious threat for young and immunocompromised individuals. The treatment is complicated because there are no approved safe and specific drugs for adenovirus infections. Here, we present evidence that 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of Hsp90 chaperone, decreases the rate of human adenovirus 5 (HAdV-5) replication in cell cultures by 95%. Read More

View Article and Full-Text PDF
February 2021

Codon Usage and Adenovirus Fitness: Implications for Vaccine Development.

Front Microbiol 2021 10;12:633946. Epub 2021 Feb 10.

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Vaccination is the most effective method to date to prevent viral diseases. It intends to mimic a naturally occurring infection while avoiding the disease, exposing our bodies to viral antigens to trigger an immune response that will protect us from future infections. Among different strategies for vaccine development, recombinant vaccines are one of the most efficient ones. Read More

View Article and Full-Text PDF
February 2021

Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.

Front Immunol 2020 29;11:607333. Epub 2021 Jan 29.

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States.

It is evident that the emergence of infectious diseases, which have the potential for spillover from animal reservoirs, pose an ongoing threat to global health. Zoonotic transmission events have increased in frequency in recent decades due to changes in human behavior, including increased international travel, the wildlife trade, deforestation, and the intensification of farming practices to meet demand for meat consumption. Influenza A viruses (IAV) possess a number of features which make them a pandemic threat and a major concern for human health. Read More

View Article and Full-Text PDF
January 2021

Fiber1, but not fiber2, is the essential fiber gene for fowl adenovirus 4 (FAdV-4).

J Gen Virol 2021 Mar 23;102(3). Epub 2021 Feb 23.

Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, PR China.

Fibre is the viral protein that mediates the attachment and infection of adenovirus to the host cell. Fowl adenovirus 4 (FAdV-4) possesses two different fibre trimers on each penton capsomere, and roles of the separate fibres remain elusive. Here, we attempted to investigate the function of FAdV-4 fibres by using reverse genetics approaches. Read More

View Article and Full-Text PDF

Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients.

Heliyon 2021 Feb 10;7(2):e06210. Epub 2021 Feb 10.

Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, USA.

Osteosarcoma is one among the most common neoplasms in dogs. Current treatments show limited efficacy and fail to prevent metastasis. Conditionally replicative adenoviruses (CRAd) replicate exclusively in targeted tumor cells and release new virus particles to infect additional cells. Read More

View Article and Full-Text PDF
February 2021

Canine interferon lambda 3 expressed using an adenoviral vector effectively induces antiviral activity against canine influenza virus.

Virus Res 2021 Apr 16;296:198342. Epub 2021 Feb 16.

Department of Infectious Diseases, College of Veterinary Medicine, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul, 05029, Republic of Korea. Electronic address:

Interferon-lambda (IFN-λ) is a type-III IFN and is considered a candidate of antiviral therapeutics. Although the antiviral effects of IFN-λ have been investigated in several studies, it has not been clinically approved as an antiviral agent. In this study, an adenoviral vector expression system employing a tetracycline-operator system was developed to control the expression of canine IFN-λ3. Read More

View Article and Full-Text PDF

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

NPJ Vaccines 2020 Jul 27;5(1):69. Epub 2020 Jul 27.

The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.

Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres. Read More

View Article and Full-Text PDF

A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

J Clin Invest 2021 03;131(5)

HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.

BACKGROUNDTo understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray.METHODSViral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Read More

View Article and Full-Text PDF

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations.

Neurosurg Focus 2021 02;50(2):E6

Departments of1Neurosurgery and.

Delta-24-based oncolytic viruses are conditional replication adenoviruses developed to selectively infect and replicate in retinoblastoma 1 (Rb)-deficient cancer cells but not normal cell with intact Rb1 pathways. Over the years, there has been a significant evolution in the design of Delta-24 based on a better understanding of the underlying basis for infection, replication, and spread within cancer. One example is the development of Delta-24-RGD (DNX-2401), where the arginine-glycine-aspartate (RGD) domain enhances the infectivity of Delta-24 for cancer cells. Read More

View Article and Full-Text PDF
February 2021

Optimization of an E1A Gene Expression Cassette in an Oncolytic Adenovirus for Efficient Tumor Cell Killing Activity.

Anticancer Res 2021 Feb;41(2):773-782

Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan;

Background/aim: Oncolytic adenoviruses (OAds) have attracted much attention as novel anticancer therapeutics. The proper design of an expression cassette containing the E1A gene, which is indispensable for self-replication of the Ad genome, is crucial for efficient tumor cell-specific infection of an OAd. Various types of oncolytic adenoviruses (OAds) possessing different types of the E1A gene expression cassettes have been developed, but their oncolytic activities and safety profiles have not been systematically evaluated. Read More

View Article and Full-Text PDF
February 2021

MAIT cell activation augments adenovirus vector vaccine immunogenicity.

Science 2021 01;371(6528):521-526

Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Mucosal-associated invariant T (MAIT) cells are innate sensors of viruses and can augment early immune responses and contribute to protection. We hypothesized that MAIT cells may have inherent adjuvant activity in vaccine platforms that use replication-incompetent adenovirus vectors. In mice and humans, ChAdOx1 (chimpanzee adenovirus Ox1) immunization robustly activated MAIT cells. Read More

View Article and Full-Text PDF
January 2021

Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein.

Sci Rep 2021 Jan 13;11(1):856. Epub 2021 Jan 13.

Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.

Adequate viral replication in tumor cells is the key to improving the anti-cancer effects of oncolytic adenovirus therapy. In this study, we introduced short hairpin RNAs against death-domain associated protein (Daxx), a repressor of adenoviral replication, and precursor terminal protein (pTP), an initiator of adenoviral genome replication, into adenoviral constructs to determine their contributions to viral replication. Both Daxx downregulation and pTP overexpression increased viral production in variety of human cancer cell lines, and the enhanced production of virus progeny resulted in more cell lysis in vitro, and tumor regression in vivo. Read More

View Article and Full-Text PDF
January 2021

Efficacy and Safety of Clinical-Grade Human Vascular Endothelial Growth Factor-D Gene Therapy Containing Residual Replication-Competent Adenoviruses.

Hum Gene Ther 2021 Mar 4. Epub 2021 Mar 4.

Heart Center, Kuopio University Hospital, Kuopio, Finland.

Biological bypass through induced angiogenesis by vascular endothelial growth factor D (VEGF-D) gene therapy (GT) is a new concept for the treatment of cardiac ischemia. Serotype 5 adenoviruses are used in the clinical trials for transferring the VEGF-D cDNA into the ischemic myocardium. However, the presence of replication-competent vectors in the adenovirus products is a widely recognized problem that may pose a potential safety risk to the treated patients. Read More

View Article and Full-Text PDF

Double-edged role of PML nuclear bodies during human adenovirus infection.

Virus Res 2021 Apr 25;295:198280. Epub 2020 Dec 25.

Institute of Virology, Hannover Medical School, Hannover, Germany; Institute of Virology, School of Medicine, Technical University of Munich, Munich, Germany; Institute of Virology Helmholtz Zentrum München, Munich, Germany; Cluster of Excellence RESIST (Resolving Infection Susceptibility, EXC 2155), Hannover Medical School, Hannover, Germany. Electronic address:

PML nuclear bodies are matrix-bound nuclear structures with a variety of functions in human cells. These nuclear domains are interferon regulated and play an essential role during virus infections involving accumulation of SUMO-dependent host and viral factors. PML-NBs are targeted and subsequently manipulated by adenoviral regulatory proteins, illustrating their crucial role during productive infection and virus-mediated oncogenic transformation. Read More

View Article and Full-Text PDF

Differential Splicing of Human Adenovirus 5 E1A RNA Expressed in versus in .

J Virol 2021 Feb 24;95(6). Epub 2021 Feb 24.

Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

Human adenovirus (HAdV) is used extensively as a vector for gene delivery for a variety of purposes, including gene therapy and vaccine development. Most adenoviral vectors used for these approaches have a deletion of early region 1 (E1), which is complemented by the cell line. Most commonly, these are 293 cells for HAdV serotype 2 or 5. Read More

View Article and Full-Text PDF
February 2021

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.

Cell Host Microbe 2021 02 16;29(2):236-249.e6. Epub 2020 Dec 16.

Institut Pasteur-TheraVectys Joint Lab, Virology Department, Institut Pasteur, Paris 75015, France; Molecular Virology and Vaccinology Unit, Virology Department, Institut Pasteur, Paris 75015, France. Electronic address:

To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in a >3 log decrease in the lung viral loads and reduces local inflammation. Read More

View Article and Full-Text PDF
February 2021

Bovine Adenovirus-3 Tropism for Bovine Leukocyte Sub-Populations.

Viruses 2020 12 12;12(12). Epub 2020 Dec 12.

VIDO-InterVac., 120 Veterinary Road, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.

A number of characteristics including lack of virulence and the ability to grow to high titers, have made bovine adenovirus-3 (BAdV-3) a vector of choice for further development as a vaccine-delivery vehicle for cattle. Despite the importance of blood leukocytes, including dendritic cells (DC), in the induction of protective immune responses, little is known about the interaction between BAdV-3 and bovine blood leukocytes. Here, we demonstrate that compared to other leukocytes, bovine blood monocytes and neutrophils are significantly transduced by BAdV404a (BAdV-3, expressing enhanced yellow green fluorescent protein [EYFP]) at a MOI of 1-5 without a significant difference in the mean fluorescence of EYFP expression. Read More

View Article and Full-Text PDF
December 2020

Species D Adenoviruses as Oncolytic Viral Vectors.

Viruses 2020 12 6;12(12). Epub 2020 Dec 6.

Nebraska Center for Virology, School of Biological Sciences, University of Nebraska, Lincoln, NE 68503, USA.

Oncolytic adenoviruses (Ad) have shown promising results in the therapeutic treatment of cancer. Ad type 5 (Ad5) is the most extensively utilized Ad type. However, several limitations exist to using Ad5 as an oncolytic virus, including high levels of anti-Ad5 neutralizing antibodies in the population, binding of the Ad5 hexon to blood coagulation factor X leading to liver sequestration and toxicity, and reduced expression of the primary receptor CAR on many tumors. Read More

View Article and Full-Text PDF
December 2020

Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection.

PLoS Negl Trop Dis 2020 12 3;14(12):e0008910. Epub 2020 Dec 3.

Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Chikungunya virus (CHIKV) is a mosquito-borne pathogen that is responsible for numerous large and geographical epidemics, causing millions of cases. However, there is no vaccine or therapeutics against CHIKV infection available. Interferon-alpha (IFN-α) has been shown to produce potent antiviral responses during viral infection. Read More

View Article and Full-Text PDF
December 2020

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Lancet Oncol 2021 01 27;22(1):107-117. Epub 2020 Nov 27.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. Read More

View Article and Full-Text PDF
January 2021

Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles Increases Its Potential as Vaccine for Serotype O Viruses.

Front Microbiol 2020 4;11:591019. Epub 2020 Nov 4.

Centro de Virología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.

Although replication-defective human adenovirus type 5 (Ad5) vectors that express the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the present study, an optimization of the Ad5 system was explored and was proven to enhance the expression of FMDV capsid proteins and their association into virus-like particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[P]) which harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome, and drives the expression of the FMDV sequences from an optimized cytomegalovirus (CMV) enhancer-promoter as well. Read More

View Article and Full-Text PDF
November 2020

Direct RNA sequencing reveals mA modifications on adenovirus RNA are necessary for efficient splicing.

Nat Commun 2020 11 26;11(1):6016. Epub 2020 Nov 26.

Division of Protective Immunity and Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

Adenovirus is a nuclear replicating DNA virus reliant on host RNA processing machinery. Processing and metabolism of cellular RNAs can be regulated by METTL3, which catalyzes the addition of N6-methyladenosine (mA) to mRNAs. While mA-modified adenoviral RNAs have been previously detected, the location and function of this mark within the infectious cycle is unknown. Read More

View Article and Full-Text PDF
November 2020

Role of CCCH-Type Zinc Finger Proteins in Human Adenovirus Infections.

Viruses 2020 11 18;12(11). Epub 2020 Nov 18.

Department of Medical Biochemistry and Microbiology, Uppsala University, 75123 Uppsala, Sweden.

The zinc finger proteins make up a significant part of the proteome and perform a huge variety of functions in the cell. The CCCH-type zinc finger proteins have gained attention due to their unusual ability to interact with RNA and thereby control different steps of RNA metabolism. Since virus infections interfere with RNA metabolism, dynamic changes in the CCCH-type zinc finger proteins and virus replication are expected to happen. Read More

View Article and Full-Text PDF
November 2020

Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus.

BMC Vet Res 2020 Nov 19;16(1):448. Epub 2020 Nov 19.

Department of Virology and Experimental Therapy, Oswaldo Cruz Foundation (FIOCRUZ), Aggeu Magalhães Research Center, Av. Moraes Rego, s/n, Campus UFPE, Cidade Universitária, Recife, PE, 50670-420, Brazil.

Background: Canine morbilivirus (canine distemper virus, CDV) is a highly contagious pathogen associated with high morbidity and mortality in susceptible carnivores. Although there are CDV vaccines available, the disease poses a huge threat to dogs and wildlife hosts due to vaccine failures and lack of effective treatment. Thus, the development of therapeutics is an urgent need to achieve rapid outbreak control and reduce mortality in target species. Read More

View Article and Full-Text PDF
November 2020

Paradoxical modulation of influenza by intranasal administration of non-replicating adenovirus particles.

PLoS One 2020 12;15(11):e0241266. Epub 2020 Nov 12.

VaxDome Inc., Commercialization Program, University of North Texas Health Science Center, Fort Worth, Texas, United States of America.

Respiratory mucosal infection by airborne microbes is a common event that occurs every day. We report here that intranasal administration of non-replicating adenovirus (Ad) particles to mice could either confer rapid protection against influenza virus (IFV) challenge independent of adaptive immunity, or exacerbate influenza by triggering rapid death. The life-or-death outcome hinges on the time interval between Ad administration and IFV challenge in conjunction with specific mouse/IFV strains. Read More

View Article and Full-Text PDF
December 2020

Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.

Cell Biosci 2020 27;10:124. Epub 2020 Oct 27.

Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070 P.R. China.

Background: Glioblastoma (GBM) is an immunosuppressive, highly vascular and devastating malignant brain tumor. Even with progressive combination treatment that includes surgery, radiotherapy, and chemotherapy, the prognosis for GBM patients is still extremely poor. Oncolytic adenovirus (OAd) can specifically replicate in GBM cells, permitting the rapid copy of the therapeutic genes it carries. Read More

View Article and Full-Text PDF
October 2020